Heartbreak to Hope: A Mother’s Mission to Cure Angelman Syndrome | Dr Allyson Berent, CSO of FAST
Nucleate PodcastShow Notes
In this episode, Allyson Berent, Chief Science Officer, Foundation For Angelman Syndrome Therapeutics (FAST), shares her remarkable journey from a career in veterinary medicine to becoming a leading advocate and innovator in the field of rare disease drug development, inspired by her daughter’s diagnosis with Angelman syndrome. She recounts the challenges of obtaining an early diagnosis, the emotional impact on her family, and her determination to find solutions where none existed. Allison describes how she immersed herself in scientific research, connected with experts, and joined the Foundation for Angelman Syndrome Therapeutics, eventually helping to launch and lead multiple initiatives aimed at accelerating the development of transformative therapies for Angelman syndrome and similar neurodevelopmental disorders. Throughout the conversation, Allison emphasizes the importance of true patient-focused drug development, sharing how her personal experience shaped her approach to building companies, running clinical trials, and fostering collaboration across the biotech ecosystem. She offers practical advice for entrepreneurs and executives, urging them to listen to patients and families, remain humble, and surround themselves with experts to address knowledge gaps. This episode highlights the profound impact that new therapies are having on patients’ lives and underscores the value of mission-driven innovation in advancing treatments for rare diseases. Time Stamps 00:02 – Introduction and Allison’s upbringing and early interest in veterinary medicine. 00:15 – Allison shares the story of how she decided to become a vet and her educational journey. 01:34 – She discusses her career as a vet, starting a family, and her daughter’s diagnosis with Angelman syndrome. 04:36 – Allison describes the early signs, medical consultations, and the process of getting a diagnosis for her daughter. 11:22 – Sam and Allison discuss the challenges of delayed diagnosis and the importance of proactive care. 13:01 – She shares stories from the community and changes in genetic testing practices. 0:14:35 – Allison explains how she and her family responded to the diagnosis and her drive to find solutions. 18:18 – She describes connecting with the foundation, joining the board, and developing a roadmap for a cure. 26:15 – The process of moving from mouse model research to human clinical trials, raising funds, and starting a company. 31:12 – Discussion on what true patient-driven development means and how it shaped Allison’s approach. 39:07 – Allison details the journey of the company, partnership with Ultragenyx, and the impact of the acquisition. 45:49 – Explanation of the accelerator model, portfolio companies, and collaborative approach to drug development. 51:20 – How the accelerator shares resources and knowledge across programs and with other companies. 52:24 – Quincy’s Progress and the Impact of New Therapies,participation in clinical trials, and the real-world impact on families. 56:05 – Sam and Allison discuss the life-changing effects of new treatments for Angelman syndrome. 58:56 – Allison offers advice on keeping the patient at the center of drug development and listening to families. 1:06:13 – She shares suggestions for integrating patient stories and perspectives into company culture and meetings. 1:09:14 – Final Words of Wisdom for Entrepreneurs: Allison emphasizes humility, gap analysis, teamwork, and resilience for those starting companies. 1:11:53 – Conclusion and Thanks
More from Nucleate Podcast
The Nucleate Podcast welcomes Matias Serebrinsky, co-founder of Psymed Ventures. Raised in Argentina by a physician father and an economist mother, he shares how his early life influenced his comfort with risk and his drive to do work that helps others. Matias shares his path from Sony marketing to starting CookUnity, and eventually to building a venture fund focused on brain and mental health.
In this episode of the Nucleate Podcast, Dr. Jo Viney, co-founder, president, and CEO of Seismic Therapeutic, shares her trajectory from academic immunology training in London to major biotech companies and startup leadership. She discusses how early clinical lab exposure to autoimmune patients sparked her passion for translational science and highlights why the Boston ecosystem is an ideal place to launch biotech startups due to its unparalleled funding, incubator space, and collaborative peer networks. She also reflects on the lessons learned from co-funding Pandion Therapeutics—including how following surprising data led to a major asset acquisition by Merck—and describes the bittersweet feeling of handing off a company she helped build.
In this episode of the Nucleate Podcast, Joe Betts-LaCroix, co-founder of Retro Biosciences, traces his path from Silicon Valley hardware startups to longevity biotech, explaining that a liquidity event from his first company prompted him to reflect on the limited real-world impact of most tech products compared to medicine, which almost always meaningfully helps people. He describes Retro's approach to navigating biotech regulation through a "daughter test" – asking whether a given regulatory requirement is one he'd genuinely want applied if it were his own family member's treatment on the line. He then explains why the company has set an ambitious but achievable mission of extending healthy human lifespan by 10 years, framing it as a "right-sized" goal for a venture-backed startup.
She started out as a small-town GP in South Africa with zero idea a "biotech industry" even existed. Three decades later, Deborah Dunsire had led the launch of Gleevec — the first targeted cancer therapy ever approved — steered Millennium Pharmaceuticals through an $8.8 billion acquisition, and run two more companies through drug failures, board showdowns, and billion-dollar bets. In this episode, she takes us inside the moments that don't make the press release: a phase one cancer patient still alive today, decades after a drug nobody thought would work; a multiple myeloma patient who happened to be trial patient #007 and was actually named James Bond; and the $60,000 milk-budget cut that nearly tanked employee morale company-wide.
In this episode of the podcast we are joined by Dr. Phillip Sharp, Nobel Prize Laureate and Institute Professor at MIT, who shares his story behind the groundbreaking discovery of RNA splicing. He explains how the work ethic and problem solving instinctions he built early on eventually led him to Caltech, and then MIT, where his 1977 discovery changed how we understand gene expression.